On one of its first studies looking at the effects of intranasal-delivered POH as a therapeutic for cancer, NeOnc Technologies Holdings, Inc. demonstrated that its NEO100 formulation had a marked therapeutic effect on patients with recurrent gliomas. The patients that were studied had become unresponsive to standard cancer therapeutic regimens and faced a dismal prognosis.

Though POH had been shown to have a cytotoxic effect on tumor cells, standard delivery of the drug through oral transport was not well tolerated by patients, and the uptake of the POH was minimal. When put on the NEO100 regimen of intranasally-delivered 0.3% v/v POH (55 mg) per dose, totaling 220 mg per day, the patients showed no signs of toxicity. The study not only demonstrated clinical activity of POH, but also revealed that long-term intranasal inhalation of the compound was very well tolerated over several years of daily use.

This study was part of the basis for NeOnc’s NEO100 GBM study conducted in 2017 which showed that NEO100 had an ability to provide improved survivability when compared to historical controls. 

Read The Paper

Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy.

Authors: Thomas C. Chen¹, Clovis O Da Fonseca², and Axel H. Schönthal³

¹Department of Neurosurgery, Keck School of Medicine, University of Southern California, Los Angeles, California, USA
²Fluminense Federal University, Niterói, Rio de Janeiro, Brazil;
³Department of Molecular Microbiology & Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA